Apiam Animal Health Limited (ASX:AHX) H1 FY24 Results Announcement
Apiam Animal Health Limited (ASX:AHX) today released its financial results for the six-months ended 31 December 2023 (H1 FY24).
Companies in the News
Biotech
Apiam Animal Health Limited (ASX:AHX) H1 FY24 Reporting Date and Investor Webinar Notification
Apiam Animal Health Limited (ASX:AHX) will release its financial results for the six months ended 31 December 2023 (H1 FY24) on Friday February 23, 2024.
VGI Health Technology Limited (NSX:VTL) New Partnership
VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has entered into a non-binding Heads of Agreement with Hebei Visual Medical Technology Co. Ltd, marking a significant step in VTL's distribution strategy into the market of the People's Republic of China.
Proteomics International Laboratories Ltd (ASX:PIQ) Investor presentation - Euroz Hartleys Healthcare Forum
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at Euroz Hartleys Healthcare Forum being held on 6 February 2024.
Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Endometriosis Blood Test
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for endometriosis, PromarkerEndo, with the clinical validation of the biomarker panel in an independent patient group.
Proteomics International Laboratories Ltd (ASX:PIQ) Study Validates Biomarkers for Oesophageal Cancer Blood Test
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce a milestone for its novel blood test for oesophageal adenocarcinoma, PromarkerEso, with the clinical validation of the biomarker panel in a second independent patient group.
Proteomics International Laboratories Ltd (ASX:PIQ) To Raise $6.5m Through Institutional Placement
Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics is pleased to announce that it has received firm commitments from new and existing institutional investors for a non-underwritten placement of 8.6 million new fully paid ordinary shares.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- Advisory Board Sharpens Focus for the 2024 Australian Gold Conference
- NSX Limited (ASX:NSX) Non-Renounceable Issue - Close of Offer and Shortfall
- ISX Financial Reports Exceptional Q4 2023 Earnings, Underlining Strong Growth and Profitability
Oil Gas & Energy
- Cobalt Blue Holdings Limited (ASX:COB) Successful A$5m Placement
- Empire Energy Group Ltd (ASX:EEG) Completes $46.8 Million Capital Raise
- Deep Yellow Limited (ASX:DYL) March 2024 Quarterly Activities Report
Life Sciences
- Proteomics International Laboratories Ltd (ASX:PIQ) March 2024 Quarterly Activities Report
- VIDEO: Apiam Animal Health Limited (ASX:AHX) MD Dr. Chris Richards Speaks with ABN Newswire on Revenue Growth in the Business
- Proteomics International Laboratories Ltd (ASX:PIQ) Investor Presentation
Social Media
